指南与共识乳腺癌妇科肿瘤

乳腺癌治疗决策中易感基因的遗传咨询与检测——欧洲共识声明与专家建议

Genetic counselling and testing of susceptibility genes for therapeutic decision-making in breast cancer-an European consensus statement and expert recommendations.
指南 / 共识 · Eur J Cancer · 2018-11-22

来自17个欧洲国家和以色列的国际专家小组召开会议,讨论BRCA检测与咨询的当前需求和未来发展并发布共识建议。专家一致认为,随着高通量检测平台的可及性增加和聚ADP核糖聚合酶抑制剂的注册,遗传咨询与检测需求将快速增长,现有遗传咨询师短缺预计将加剧并影响疑似或确诊遗传性乳腺癌或卵巢癌个体及家庭的照护质量。在治疗场景中,对于临床怀疑遗传易感性且结果可能对治疗策略有直接影响的患者,多数投票认为应在乳腺癌组织学诊断后进行BRCA1/2检测,无论雌激素受体和人表皮生长因子受体2(HER2)状态如何。

要点

  • 多数专家投票认为,临床怀疑遗传易感性且结果可能立即影响治疗策略时,应在乳腺癌组织学诊断后行BRCA1/2检测,不论ER和HER2状态。
  • 预测和治疗场景下,遗传检测应限于有提示BRCA1/2致病性变异个人史或家族史的个体,并应包括BRCA1/2以外的高风险可干预基因。
  • 高风险可干预基因中,所有致病性变异(即IV类和V类)均应报告;意义未明的III类变异应在明确说明当前缺乏临床效用的情况下报告。

核心结论

  • 专家一致认为,随着高通量检测平台可及性增加和聚ADP核糖聚合酶抑制剂注册,遗传咨询与检测需求将快速增长,现有遗传咨询师短缺预计将加剧并影响照护质量。

研究设计与样本

  • 代表17个欧洲国家和以色列的国际专家小组召开会议,讨论BRCA检测与咨询的当前需求和未来发展并发布共识建议。

主要发现

  • 专家一致认为,随着高通量检测平台可及性增加和聚ADP核糖聚合酶抑制剂注册,遗传咨询与检测需求将快速增长。
  • 现有遗传咨询师短缺预计将加剧,并影响疑似或确诊遗传性乳腺癌或卵巢癌个体及家庭的照护质量。
  • 增加乳腺癌照护者社区的教育努力可能通过使所有相关专科能够进行遗传咨询来缓解这一限制。

关键数值与推荐

  • 在治疗场景中,对于临床怀疑遗传易感性且结果可能对治疗策略有直接影响的患者,多数投票认为应在乳腺癌组织学诊断后进行BRCA1/2检测,无论雌激素受体和人表皮生长因子受体2(HER2)状态如何。
  • 专家还一致认为,在预测和治疗场景下,遗传检测应限于有提示BRCA1/2致病性变异个人史或家族史的个体,并应包括BRCA1/2以外的高风险可干预基因。
  • 高风险可干预基因中,所有致病性变异(即IV类和V类)均应报告;意义未明的III类变异应在明确说明当前缺乏临床效用的情况下报告。
  • 遗传咨询应始终讨论已检测个体可能因特定变异的新信息导致重新分类而被重新联系的可能性。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

An international panel of experts representing 17 European countries and Israel convened to discuss current needs and future developments in BRCA testing and counselling and to issue consensus recommendations. The experts agreed that, with the increasing availability of high-throughput testing platforms and the registration of poly-ADP-ribose-polymerase inhibitors, the need for genetic counselling and testing will rapidly increase in the near future. Consequently, the already existing shortage of genetic counsellors is expected to worsen and to compromise the quality of care particularly in individuals and families with suspected or proven hereditary breast or ovarian cancer. Increasing educational efforts within the breast cancer caregiver community may alleviate this limitation by enabling all involved specialities to perform genetic counselling. In the therapeutic setting, for patients with a clinical suspicion of genetic susceptibility and if the results may have an immediate impact on the therapeutic strategy, the majority voted that BRCA1/2 testing should be performed after histological diagnosis of breast cancer, regardless of oestrogen receptor and human epidermal growth factor receptor 2 (HER2) status. Experts also agreed that, in the predictive and therapeutic setting, genetic testing should be limited to individuals with a personal or family history suggestive of a BRCA1/2 pathogenic variant and should also include high-risk actionable genes beyond BRCA1/2. Of high-risk actionable genes, all pathological variants (i.e. class IV and V) should be reported; class III variants of unknown significance, should be reported provided that the current lack of clinical utility of the variant is expressly stated. Genetic counselling should always address the possibility that already tested individuals might be re-contacted in case new information on a particular variant results in a re-classification.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Singer CF, Balmaña J, Bürki N, et al. Genetic counselling and testing of susceptibility genes for therapeutic decision-making in breast cancer-an European consensus statement and expert recommendations. Eur J Cancer. 2018. PMID: 30471648. doi:10.1016/j.ejca.2018.10.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。